SEC Filing Summary: Form 6-K
Business Context and Reporting Period
This Form 6-K is filed by Hong Kong Pharma Digital Technology Holdings Limited (not Cellyan Biotechnology Co., Ltd as indicated in metadata) for the month of March 2025, with a filing date of March 28, 2025. The registrant is a foreign private issuer headquartered in Hong Kong. The filing serves as a report of current events and includes exhibits rather than a full financial statement for the current period.
Key Financial Metrics
The filing text does not provide specific financial metrics (revenue, profit, cash flow, margins, debt, or liquidity) for the period ending March 2025. The document references Exhibit 99.1, which contains Unaudited Interim Consolidated Financial Statements as of September 30, 2024, and for the six months ended September 30, 2024, and 2023. No numerical values from these statements are included in the provided text.
Material Changes
The filing text does not explicitly detail material changes versus prior periods. It lists a Press Release dated March 28, 2025 (Exhibit 99.2) as an attachment, which likely contains the material event triggering this filing, but the content of the press release is not provided in the source text.
Guidance, Outlook, and Risks
The provided text contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The document is a cover sheet and exhibit index.
Investor Verification Checklist
- Verify the correct registrant name: The filing is for Hong Kong Pharma Digital Technology Holdings Limited, not Cellyan Biotechnology Co., Ltd.
- Review Exhibit 99.2 (Press Release dated March 28, 2025) to understand the specific event reported in this 6-K.
- Consult Exhibit 99.1 for the most recent available financial data (as of September 30, 2024), as no Q1 2025 data is present in this text.
- Confirm the company's reporting status as a foreign private issuer filing under Form 20-F.